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Abstract. Targeting the hypoxia response pathway and angio-
genesis are two promising therapeutic strategies for cancer 
treatment. Their use as single strategies has important limita-
tions. Thus, development of combined regimens has become 
an important step toward improving therapeutic efficacy. Also, 
non-invasive monitoring of the response to targeted biological 
therapies, as well as determination of the optimal schedule for 
combination regimens has become an active field of research 
over the last five years, with relevance for both preclinical and 
clinical settings. Here, we used an optical imaging method to 
non-invasively monitor the functional changes in HIF activity 
in response to antiangiogenic treatment in a xenograft model 
of human ovarian carcinoma. A bioluminescent reporter 
construct containing nine copies of the hypoxia response 
element upstream of the luciferase gene (9xHRE-luciferase) 
was characterized in vitro in a panel of tumor cell lines and 
in vivo in a subcutaneous xenograft model of ovarian carcinoma 
by means of optical imaging. We showed that in OVCAR-3 
subcutaneous xenografts, the most abrupt change in the HIF 
functional reporter occurs before the onset of massive tumor 
growth. However, this system failed to detect hypoxia induced 
upon antiangiogenic treatment due to the compensating effects 
of increased hypoxia and decreased tumor cell viability 
caused by imbalanced neovascularization vs. tumor expansion. 
Therefore, the readout based on HIF functional reporter could 
be conditioned by the dynamics of tumor growth and angio-
genesis, which is highly variable depending on the tumor type, 
tumor model and stage of progression.
Introduction
Oxygen availability is a fundamental restriction to the unlim-
ited proliferative capacity characteristic of tumor cells. Thus, 
hypoxia is a common feature of most solid tumors. To surpass 
this barrier, tumor cells must evolve to acquire angiogenic 
potential, which endows them with the capacity to grow locally 
leading to tumor mass expansion. Therefore, suboptimal oxygen 
concentration (hypoxia) is one of the most relevant triggers of 
tumor angiogenesis and consequently the growth of tumors 
can be viewed as driven by cycles of hypoxia and angiogen-
esis. Taking these biological restrictions into account, halting 
angiogenesis has emerged as a general principle in which new 
antitumor therapies could be based.
Over the last 30 years knowledge of the molecular and 
cellular basis of tumor angiogenesis has led to the development 
of a large number of antiangiogenic strategies, some of which 
are at present in clinical use (1,2). However, the biological output 
of antiangiogenic therapy has not been fully deciphered yet and 
may be variable depending on the tumor type, progression of 
the disease and antiangiogenic strategy. It is widely accepted 
that the dynamics of antiangiogenic drug response are initiated 
by an early phase of functional normalization of the tumor 
vasculature (early or normalization phase) characterized by an 
increased pericyte coverage and a decreased basal membrane 
thickness and vessel diameter; which results in improved 
tumor oxygenation (3). This functional normalization phase is 
followed by vessel regression caused by selective induction of 
apoptosis on tumor endothelial cells (late or regression phase); 
which results in impaired tumor perfusion and induction of 
necrotic tumor cell death; leading to the desired antitumor 
effect. Yet sustained hypoxia gives raise to one of the main 
modes of resistance to antiangiogenic therapy, as new inducers 
of angiogenesis are produced by tumor cells under the selective 
pressure of tumor hypoxia generated by chronic antiangiogenic 
treatment (4).
Monitoring of the response to antiangiogenic drugs based 
on diverse functional, cellular and molecular parameters is of 
critical importance both at preclinical and clinical settings in 
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order to evaluate the benefits and limitations of antiangiogenic 
therapy for cancer treatment (5). Generation of tumor hypoxia 
by antiangiogenic treatment has been anticipated as a relevant 
biological output. Changes in oxygen tension are sensed by a 
family of HIF-prolyl hydroxylases (6-8) which, together with 
the product of the tumor suppressor gene VHL (9), control 
the stability of the α subunit of the hypoxia inducible factors 
HIF (HIF1, HIF2/EPAS and HIF3). Under hypoxia the HIFα 
subunits escape degradation, accumulate and bind to the 
constitutive HIFβ subunit (10). The α/β heterodimer consti-
tutes the active HIF factor that is responsible for most of the 
genetic reprogramming induced to cope with fluctuations in 
oxygen tension deviated from the optimum. To which extent 
antiangiogenic treatment induces tumor hypoxia is still not 
properly described and could be variable depending on the 
antiangiogenic drug, tumor type or experimental model.
In order to address this point we used an optical imaging 
method to non-invasively monitor functional changes in HIF 
activity in response to antiangiogenic drugs in a xenograft 
model of human ovarian carcinoma. A bioluminescent reporter 
construct containing nine copies of the hypoxia response 
element upstream of the luciferase gene (9xHRE-luciferase) 
was characterized in vitro in a panel of tumor cell lines and 
in vivo in a subcutaneous xenograft model of ovarian carci-
noma. Subsequently, the 9xHRE-luciferase reporter was used to 
monitor the effect of antiangiogenic treatment on HIF activity 
using optical imaging. Variations on the functional activity of 
HIF were next correlated with relevant biological responses such 
as angiogenesis, hypoxia and tumor cell viability monitored 
ex vivo by standard methods. Our results show that monitoring 
of the 9xHRE-luciferase reporter by optical imaging in a 
subcutaneous xenograft model of ovarian carcinoma allowed 
us to detect hypoxic areas due to an imbalance between tumor 
growth and new capillary formation. However, this system has 
limitations to detect changes in HIF activity induced by anti-
angiogenic treatment due to the opposing effects on the HIF 
reporter of simultaneous induction of hypoxia and decrease in 
cell viability caused by tumor vessel regression.
Materials and methods
Cell lines and reagents. Cervix (HeLa), prostate (PC3), 
pancreatic (BxPC3) and ovarian (OVCAR-3, SKOV-3) human 
carcinoma cell lines were purchased from the American Type 
Culture Collection (ATCC, Rockville, MD). UCD-Mel-N was 
derived from a patient with multiple primary melanoma tumors 
and generously provided by Dr E. Medrano (11). pVHL-
deficient 786-O cell clones stably expressing wild-type VHL 
(786-O-WT10) or empty plasmid (786-O-PCR3) were kindly 
provided by Dr W. Kaelin (Dana-Farber Institute, Boston, MA). 
HeLa cells were cultured in DMEM and the other cell lines 
were maintained in RPMI-1640. In all cases, culture media 
were supplemented with 100 U/ml penicillin and 100 µg/ml 
streptomycin, 2 mM glutamine and 10% fetal bovine serum. 
Cells were incubated at 37˚C in a well-humidified incubator 
with 5% CO2 and 95% air.
Generation of stably transfected OVCAR-3-9xHRE-luc 
cells. OVCAR-3-9xHRE-luc cells expressing the luciferase 
gene under the control of nine tamdem copies of the hypoxia 
response element (9xHRE) were generated by co-transfeccion 
of 9xHRE-luc plasmid (12) and a hygromycin resistance 
plasmid at a 5:1 ratio using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA). After selection with 50 µg/ml hygromycin in 
culture medium, antibiotic-resistant cells were selected and 
established as a stable pool which was tested in vitro and used 
in the in vivo studies.
HIF reporter in vitro assay and detection of HIF stabilization 
by Western blot analysis. Cells were transfected by lipofection 
(Lipofectamine 2000; Invitrogen) with the HIF-responsive 
firefly luciferase reporter (12) and a Renilla luciferase expres-
sion plasmid at a 5:1 ratio. After transfection cells were split 
into 24-well plates and 20-24 h after plating, cells were exposed 
to hypoxia (1% oxygen, Whitley H35 Hypoxystation; Don 
Whitley Scientific, UK), 1 mM DMOG (Biomol International, 
Plymouth Meeting, PA) or left untreated for 6 additional hours. 
Then, cells were harvested and firefly and Renilla luciferase 
activities were determined using a Dual Luciferase System 
(Promega, Madison, WI). Firefly luciferase activity was 
normalized based on the Renilla luciferase activity.
The level of HIF1-α, HIF2-α and tubulin protein expression 
was determined by Western blotting. Anti-HIF1-α (Ab2185), 
anti-HIF2-α (Ab199) and anti-tubulin were purchased 
from Transduction Laboratories, from Novus Biologicals 
(Littleton, CO), and from Sigma (St. Louis, MO), respectively. 
Immunolabeling was detected by enhanced chemiluminescence 
(Amersham Pharmacia Biotechnology, Piscataway, NJ) and 
visualized with a digital luminescent image analyzer (Fujifilm 
LAS-1000 CH).
Subcutaneous xenografts and bioluminiscence imaging. 
OVCAR-3-9xHRE-luc cells (4x106) were resuspended in 
100 µl PBS and subcutaneously injected into the dorsal flank 
of 6- to 8-week-old nude mice (BALB/c nu/nu, Harlan). 
Monitoring of tumor-bearing mice was initiated 2 days after 
implantation. Tumor volume was measured every 2-3 days 
using a caliper and calculated using the equation: D x (d)2/2, 
where D and d are respectively the major and minor diameters. 
Animals were maintained under specific pathogen-free condi-
tions and treated according to the protocol approved by the 
Universidad Autónoma de Madrid Animal Care Committee.
For the in vivo studies using antiangiogenic drugs, experi-
mental groups (n=5) were randomly established and treatments 
were initiated 11 days after tumor cell inoculation. Bevacizumab 
(Avastin®, Roche) was obtained from the Pharmacy Service of 
Virgen de la Victoria University Hospital. It was i.p. injected 
every 2-3 days in a dose of 5 mg/kg. ABT-510 (Abbott 
Laboratories, Abbott Park, IL) was injected i.p. daily in a dose 
of 100 mg/kg. The control group was i.p. injected with an equal 
volume of PBS. Bioluminiscence imaging was performed as 
described below every 2-3 days before and during the treatment.
Twenty-five days after tumor inoculation, mice were eutha-
nized, tumors were removed, embedded in OCT and frozen in 
liquid nitrogen for immunofluorescence studies.
For the in vivo bioluminiscence imaging experiments, 
the tumor-bearing mice were i.p. injected with 10 µl/g of 
D-luciferin solution (10 mg/ml in PBS, Promega), and subjected 
to imaging using an IVIS-Lumina in vivo imaging system and 
Living Image software (Xenogen-Calliper, San Francisco, 
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CA). Bioluminescent images were acquired after the luciferin 
injection during 30 min and the maximum value of the image 
sequence was used for each animal.
Where indicated, animals were exposed to an 8% O2 
atmosphere for 14-16 h (Whitley H35 Hypoxystation). In these 
experiments, bioluminiscence values were measured just before 
and after exposure to hypoxia.
In vivo Matrigel plug assay. BALB/c nu/nu mice were injected 
s.c. with 300 µl of Matrigel containing basic fibroblast growth 
factor (bFGF; 0.5 µg/ml) alone (control) or in combination with 
1-10 µM ABT-510 (ABT group). Mice were sacrificed 10 days 
after injection. Plugs were then removed, embedded in OCT 
and frozen in liquid nitrogen for immunofluorescence studies.
CD31 detection in Matrigel plugs and tumors. For immunode-
tection of CD31, 10 µm sections were fixed in acetone, blocked 
with 3% BSA in PBS and incubated at 4˚C overnight with anti-
CD31 antibody (BD Biosciences Pharmingen, San Deigo, CA). 
The anti-mouse Alexa-546 secondary antibody (Invitrogen) was 
used to detect the CD31 signal and DAPI to stain cell nuclei. 
Quantification of the CD31-positive area was performed using 
the NIH ImageJ analysis software. Mean values of at least 10 
fields of 3 sections were calculated for each sample.
Evaluation of tumor hypoxia and quantification of tumor 
necrosis. To evaluate the presence of hypoxic areas in 
tumors we used the nitroimidazole derivative pimonidazole 
(Hypoxyprobe™, HPI, Inc.). Pimonidazole hydrochloride 
(60 mg/kg) was injected i.v. into tumor-bearing mice and after 
1 h animals were sacrificed. Excised tumors were fixed in 4% 
paraformaldehyde, embedded in OCT and frozen in liquid 
nitrogen. Sections of 10 µm were prepared and immunodetec-
tion of pimonidazole was performed using anti-pimonidazole 
antibody (HPI, Inc.). Images were acquired using a Nikon TS100 
(Nikon, Inc., Melville, NY) inverted phase contrast microscope 
with a DS-5M-L1 (Nikon) photomicrographic camera system. 
Total hypoxic area in tumor sections was determined by scoring 
diaminobenzidine (DAB)-positive pixels in x100 magnification 
images using the NIH ImageJ analysis software. Two tumor 
sections were analyzed for each experimental condition and the 
mean value ± SD was determined.
Tumor necrosis was evaluated by standard hematoxylin and 
eosin (H&E) staining. Brieftly, frozen sections were thawed, 
fixed in cold acetone, stained using Mayer's hematoxylin for 
1 min and counterstained with eosin. Quantification was 
performed as indicated for pimonidazole staining. Four tumors 
were analyzed for each experimental condition and the mean 
value ± SD was determined.
Results
In vitro functional evaluation of 9xHRE-luciferase reporter 
in a panel of tumor cell lines. Generation of hypoxic areas 
in tumors can be quantified indirectly by using reporter 
vectors in which the reporter gene is controlled by a tandem 
of hypoxia-response elements (HREs). We used the 9xHRE-
luciferase (9xHRE-luc) reporter vector that harbors nine 
copies of the HRE derived from the VEGFA gene upstream of 
a minimal rat prolactin promoter driving the expression of the 
firefly luciferase gene (12). Similar vectors, containing a vari-
able number of HREs and diverse reporter genes (luciferase or 
EGFP) have been developed and used as functional reporters 
for optical imaging over the last 5 years (13-19). Hypoxic 
conditions lead to hypoxia inducible factor (HIF) stabilization 
and subsequent induction of luciferase reporter gene expres-
sion through binding of HIF to HREs in the reporter and 
activation of transcription driven by HIF.
We first evaluated the suitability of 9xHRE-luc as a bona 
fide hypoxia inducible reporter in a panel of human tumor 
cell lines transiently transfected with 9xHRE-luc; including 
melanoma (UCD-Mel-N), cervix (HeLa), prostate (PC3), 
renal (786-O-PRC3, 786-O-WT10), pancreatic (BxPC3) and 
ovarian (OVCAR-3, SKOV-3) carcinomas. Reliability of our 
reporter system was demonstrated by lack of basal activity in 
786-O-WT10 cells as compared to 786-O-PRC3 cells (Fig. 1A, 
left graph). 786-O-PRC3 cells are derived from a clear cell 
renal carcinoma lacking functional VHL protein. pVHL is the 
substrate recognition subunit of an E3-ubiquitin ligase complex 
that targets HIF for proteasomal degradation under normoxia. 
Thus, 786-O-PRC3 cells show a high basal activity of HIF that 
is abolished upon forced expression of a normal VHL gene as 
is the case of the 786-O-WT10 clone. Analysis of these results 
(Fig. 1A, left graph) revealed a subset of tumor cell lines in 
which the basal level of the reporter activity was very low 
(HeLa and OVCAR-3) as compared to others that displayed 
significant basal levels of HIF-mediated transcription (PC3, 
SKOV-3, BxPC3, UCD-Mel-N). The increased basal activity 
observed in PC3 cells can be explained by the amplification 
of the HIF locus described in this cell type (20). Induction of 
9xHRE-luc reporter by hypoxia (Fig. 1A, middle graph) and 
the hypoxia mimetic DMOG (Fig. 1A, right graph) ranged from 
10- to 100-fold and the stabilization of HIF1-α or HIF2-α under 
hypoxia was confirmed by Western blot analysis (Fig. 1B), with 
the induction of HIF-α being more evident in most cell lines.
Based on these results, the ovarian carcinoma cell line 
OVCAR-3-9xHRE-luc was selected for subsequent in vivo 
studies due to its low basal HIF activity and large inducibility 
of the reporter upon hypoxia.
In vivo functional evaluation of 9xHRE-luciferase reporter by 
optical imaging in subcutaneous xenografts of ovarian carci-
noma. 9xHRE-luc reporter was next evaluated in vivo using 
bioluminescence optical imaging in a subcutaneous xenograft 
model of ovarian carcinoma. To this end we generated the 
OVCAR-3-9xHRE-luc cell line by stable transfection of 
OVCAR-3 cells with the 9xHRE-luc construct. This cell line 
was injected s.c. in nude mice and the bioluminiscent signal 
(Total Flux, photons/sec) was monitored, on a daily basis, 
after the administration of D-luciferin. A sequence of optical 
images and the corresponding data of Total Flux vs. time after 
implantation are shown in Fig. 2A. The dynamics of 9xHRE-
luc reporter activity in growing tumors displayed three distinct 
phases. We first observed a gradual decrease in Total Flux 
corresponding to the initial phase of establishment of the 
tumor (from the day of s.c. injection up to day 7-10) during 
which many tumor cells died (‘9xHRE-luc reporter establish-
ment phase’, data not shown). This was followed by a large 
increase in Total Flux (Fig. 2B left, Total Flux vs. tumor size 
logarithmic scale) in the absence of detectable tumor growth 
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(‘9xHRE-luc reporter exponential phase’). This initial burst 
of reporter activity was followed by a gradual/linear increase 
in Total Flux (Fig. 2B right, Total Flux vs. tumor size, linear 
scale) that paralleled an increase in tumor size (‘9xHRE-luc 
reporter linear phase’).
In vivo induction of 9xHRE-luc reporter by hypoxia in the 
tumor setting was directly demonstrated by introducing tumor 
bearing mice in a hypoxia work station. As shown in Fig. 2C, 
the Total Flux in tumors from animals exposed to an 8% 
oxygen atmosphere for 14-16 h (hypoxic condition) increased 
16-fold relative to Total Flux in tumors from animals kept at 
normoxic conditions.
Together these results indicate that the system based on the 
9xHRE-bioluminiscent reporter is able to monitor changes in 
tumor hypoxia in vivo by means of optical imaging. This system 
allowed us identify a specific pattern of hypoxia dynamics 
during the growth of subcutaneous OVCAR-3 xenografts.
Monitoring of the response to antiangiogenic treatment by 
optical imaging using the 9xHRE-luciferase reporter in 
subcutaneous xenografts of ovarian carcinoma. We next 
investigated the suitability of this reporter to indirectly detect 
variations in tumor oxygenation caused by treatment with two 
types of antiangiogenic strategies: i) bevacizumab, a human-
ized monoclonal antibody against vascular endothelial growth 
factor-A and ii) ABT-510, a peptide mimetic of the endogenous 
inhibitor of angiogenesis thrombospondin-1. Antiangiogenic 
treatment was initiated on day 11 after the inoculation of 
tumor cells in nude mice; therefore, our experimental design 
was intended to evaluate the effect of inhibition of angiogen-
esis on the ‘9xHRE-luc reporter linear phase’. Comparison 
of Total Flux vs. tumor size in the three experimental groups 
(control, bevacizumab and ABT-510) showed that, in spite of 
a similar initial ‘exponential phase’ (Fig. 3A, lower panels), 
bevacizumab induced a decrease in large tumors corre-
sponding to the ‘linear phase’ (Fig. 3A, upper panels), while 
there was no significant effect of ABT-510 in the subcutaneous 
xenograft ovarian carcinoma model (Fig. 3A, top panels). 
Representation of variation of Total Flux during the treatment 
period (increase in Total Flux from day 11 to day 25) for the 
three experimental groups confirmed that bevacizumab, but 
not ABT-510, treatment significantly (p<0.05) reduced Total 
Flux (Fig. 3B).
A potential explanation for this unexpected result is that 
D-luciferin delivery to hypoxic regions could be compro-
mised by the antiangiogenic effect of bevacizumab treatment. 
However, exposure of mice to hypoxia led to a similar induc-
tion of 9xHRE-luc reporter in tumors from control, ABT-510 
and bevacizumab groups (Fig. 3C), arguing against such a 
possibility.
Ex vivo evaluation of antiangiogenic treatment in subcutaneous 
xenografts of ovarian carcinoma. We next intended to correlate 
variations in 9xHRE-luc reporter in response to bevacizumab 
Figure 1. In vitro characterization of the 9xHRE-luciferase reporter in a panel of tumor cell lines. (A) The activity of the 9xHRE-luciferase reporter was 
measured in a panel of tumor cell lines including melanoma (UCD-Mel-N), cervix (HeLa), prostate (PC3), renal (786-O-PRC3, 786-O-WT10), pancreatic 
(BxPC3) and ovarian (OVCAR-3, SKOV-3) carcinoma cell lines, transiently transfected with the 9xHRE-luc reporter contruct. Basal activity (left graph), fold 
induction by hypoxia (middle graph) and fold induction by DMOG (right graph) are shown. Graphs represent values obtained from three independent experi-
ments (▲, ◼, ◆) and their mean (-). In the middle and right graphs the values of luciferase activity (corrected by Renilla activity) upon treatments (hypoxia/
DMOG) are represented as the fold over the the normoxic values. (B) HIF1-α and HIF2-α stabilization by hypoxia was evaluated by Western blot analysis in 
the panel of tumor cell lines used in (A). Tubulin was used as loading control.
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with relevant biological outputs that might be predictive of a 
biological response to bevacizumab; such as tumor angiogen-
esis, tumor hypoxia and tumor cell viability evaluated ex vivo 
in tumor sections by standard methods.
Bevacizumab treatment of subcutaneous tumors of 
OVCAR-3-9xHRE-luc cells reduced tumor microvascular 
density by ~2-fold after 14 days of treatment (Fig. 4A, top 
images and lower left graph). The response to ABT-510 in the 
Figure 2. Functional evaluation of the 9xHRE-luciferase reporter by bioluminescence imaging during in vivo growth of subcutaneous xenografts of 
OVCAR-3-9xHRE-luc cells. (A) Activity of 9xHRE-luciferase reporter was monitored by bioluminescence imaging during growth of subcutaneous xeno-
grafts of OVCAR-3-9xHRE-luc cells in immunodeficient mice. Mice were imaged on day 8 and subsequently every 1-3 days until day 23. A temporal 
sequence of images of a representative tumor is shown (upper panels). Total bioluminiscence photon counts (Total Flux, photons/sec) and tumor size (cm3) 
were represented vs. time (days) (lower left and right graphs, respectively). (B) Total bioluminiscent photon counts (Total Flux, photons/sec) were represented 
vs. tumor size (cm3) using a logaritmic scale (left) or a linear scale (right). (C) Induction of 9xHRE-luciferase reporter in subcutaneous tumors by hypoxia 
in vivo. Mice were kept under hypoxia for 16 h prior to D-luciferin injection and imaging. Representative images of tumors before (normoxia) and after 
hypoxia are shown (left). Total bioluminiscence photon counts (Total Flux, photons/sec) were represented for tumors in normoxia (N) and hypoxia (H) (right).
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OVCAR-3-9xHRE-luc tumors was highly variable and there 
were no significant differences in the mean tumor microvas-
cular density between control and ABT-510 groups (Fig. 4A). 
In contrast, ABT-510 showed a marked antiangiogenic effect 
in vivo in a matrigel plug assay (Fig. 4B), confirming that 
this reagent has the expected biological activity. Hence, these 
result suggested that OVCAR-3 subcutaneous xenografts were 
sensitive to bevacizumab, but not ABT-510, treatment.
In agreement with their effect on the vasculature of 
OVCAR-3-derived tumors, bevacizumab, but not ABT-510, 
treatment consistently reduced tumor size, while there was no 
relevant change in the ABT-510 experimental group compared 
to the control group (Fig. 4A, lower right graph). Despite of 
their trend, differences did not reach statistical significance 
due to the variability in the control group.
Next, we analyzed the effect of antiangiogenic treatment on 
tumor hypoxia by injection of the nitroimidazole derivative pimo-
nidazole 1 h before tumor collection and subsequent detection of 
pimonidazole adducts by staining with a peroxidase-conjugated 
hypoxyprobe antibody. Growth of OVCAR-3-9xHRE-luc 
tumors significantly induced tumor hypoxia. Significant fields 
for the control, bevacizumab and ABT-510 experimental groups 
are shown for day 30 in Fig. 5A. Also a representative field 
for pimonidazole staning for the control group at day 11 was 
included in Fig. 5A (upper left image). We monitored possible 
differences in pimonidazole staining on day 30 between the 
control, ABT-510 and bevacizumab groups. We found no 
significant differences comparing the control with ABT-510 
(Fig. 5A). Surprisingly, tumors from bevacizumab-treated mice 
were negative for pimonidazole staining (Fig. 5A). This result 
could be explained by compromised pimonidazole delivery due 
to tumor vessel regression caused by bevacizumab treatment 
as was recently described in a model of PC3 carcinoma (21). 
However, monitoring of the HIF reporter was not compromised 
in the bevacizumab-treated group (Fig. 3B) arguing against this 
possibility.
Finally, the effect of antiangiogenic treatment on tumor 
cell viability was estimated by H&E staining. Consistent with 
Figure 3. Real-time, non-invasive monitoring of the effect of antiangiogenic treatment on HIF1-α activation by bioluminescent imaging in subcutaneous xeno-
grafts of OVCAR-3-9xHRE-luc cells. (A) Total bioluminiscence photon counts (Total Flux, photons/sec) were represented vs. tumor size (cm3) for control 
(left), bevacizumab (middle) and ABT-510 (right) using a linear scale (upper graphs) or a logaritmic scale (lower graphs). (B) Mean total bioluminiscence 
photon counts at day 25 (end of experiment) minus day 11 (beginning of antiangiogenic treatment), were represented for each experimental group (control, 
bevacizumab, ABT-510). The graph represent the average values for each group and their standard deviation. (C) Total bioluminiscence photon counts (Total 
Flux, photons/sec) were determined in mice from each experimental group (control, bevacizumab, ABT-510) exposed to hypoxia at the end of the experiment 
(day 25). The graph represents bioluminiscence photon counts after 16-h exposure to hypoxia as a fold over the counts prior to exposure to hypoxia.
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the induction of hypoxia during the growth of OVCAR-3-
9xHRE-luc tumors, there was an increase in the percentage of 
necrotic tumor areas (Fig. 5B). Induction of necrosis was highly 
variable among different types of subcutaneous tumors in immu-
nodeficient mice; ranging from no necrosis such as in HeLa and 
UCD-Mel-N tumors (data not shown), to highly represented 
necrosis in OVCAR-3 tumors (Fig. 5B). Treatment of OVCAR-
3-9xHRE-luc tumors with bevacizumab, but not ABT-510, 
resulted in a further 15% increase in the necrotic area (Fig. 5C). 
We observed that changes induced by bevacizumab in 9xHRE-
luc reporter activity were larger than the reduction of tumor size 
caused by bevacizumab treatment (Fig. 3A). This discrepancy 
could be explained by the decreased number of viable tumor 
cells in the bevacizumab treated group.
Discussion
As a result of uncontrolled proliferation, tumor cells outgrow 
their vascular supply territories, thus originating hypoxic 
areas within the tumor mass. The adaptation of tumor cells 
to decreased oxygen availability is mastered by hypoxia 
inducible factors (HIFs), which coordinate an extensive repro-
gramming of gene expression aimed to adjust metabolism 
to suboptimal oxygen concentrations and to increase oxygen 
Figure 4. Quantification of the antiangiogenic effect of bevacizumab and ABT-510. (A) The antiangiogenic effect of bevacizumab and ABT-510 on subcu-
taneous xenografts was evaluated by CD31 immunostaining of tumor sections. DAPI staining was used to evaluate the cellular density in selected fields. 
Representative images of tumor sections from control, bevacizumab or ABT-510 experimental groups are shown (upper panels). Percentage of CD31 positive 
staining is shown relative to the control group (lower graph, left). The graph represents the average values obtained in 10 independent fields and the standard 
deviation. Mean tumor size at day 30 (end of experiment) minus day 11 (beginning of antiangiogenic treatment), was represented for each experimental group 
(control, bevacizumab, ABT-510) (lower right graph). (B) The biological activity of ABT-510 was verified using the Matrigel plug assay. Angiogenesis was 
evaluated by CD31 immunostaining of plug sections. DAPI staining was used to evaluate cellular density in selected fields. Representative images of plug 
sections from control (bFGF), bFGF plus ABT-510 at different concentrations are shown (left panels). Percentage of CD31 positive staining is shown relative 
to the control group (right graph). The graph represents the average values obtained in 10 independent fields and the standard deviation.
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delivery by inducing the formation of new blood vessels. 
Furthermore, in the tumor context hypoxic driven reprogram-
ming correlates with increased metastatic potential and highly 
hypoxic tumors are often associated with poor prognosis and 
worse response to chemotherapy or radiotherapy (22).
Relevance of tumor hypoxia and HIFs in cancer progres-
sion has led to the development of HIF-targeting strategies 
(17,22-24) and non-invasive in vivo imaging techniques to 
monitor intratumoral hypoxia or HIF stabilization or activation 
(25-27). In addition to the activation of the HIF pathway as a 
consequence of tumoral hypoxia, specific genetic lesions lead 
to the constitutive stabilization of HIF, the paradigm being the 
inactivation of VHL in clear cell carcinomas and pheochro-
mocytomas (28). Moreover, the constitutive activation of HIF 
seems to be central to the generation and progression of some 
tumors (29). In this regard, we found that several tumoral cell 
lines displayed high basal (normoxic) HIF activity (Fig. 1A). 
In the case of the prostate cancer PC3 cells, this activity is 
expected to be a consequence of the amplification of the HIF 
locus described for this cell type (20). In agreement, PC3 cells 
display a high basal level of HIF1-α protein (Fig. 1B). However, 
we do not know the reason for the high basal HIF activity found 
in SKOV-3, BxPC3 and UCD-Mel-N cells. Intriguingly, in these 
cases, increased HIF activity is not paralleled by accumulation 
of HIFα proteins. Regardless of the molecular mechanism, our 
results suggest that constitutive HIF activity could be a more 
general feature of tumors than previously recognized, under-
lying the importance of this molecule as a therapeutic target.
Effectiveness of some HIF targeting strategies (23) could 
be improved by combination with antiangiogenic strategies, 
which are expected to further increase tumor hypoxia. To this 
end monitoring of the impact of antiangiogenic therapy on the 
HIF pathway is of critical importance for the evaluation of the 
tumor's response to the antiangiogenic regimen and to define 
the right schedule for the combination therapy using HIF 
inhibitors. Here we used an optical imaging method to non-
invasively monitor functional changes in HIF activity during 
growth of subcutaneous xenografts of the ovarian carcinoma 
cell line OVCAR-3 and in response to antiangiogenic therapy. 
OVCAR-3 cells cultured in vitro under normoxic conditions 
displayed very low basal levels of our functional bioluminiscent 
HIF reporter (9xHRE-luc) and high inducibility (30-fold) under 
hypoxic conditions. Remarkably, in vivo, HIF reporter activity 
increased by orders of magnitude without apparent tumor 
Figure 5. Quantification of the effect of antiangiogenic treatment on tumor hypoxia and necrosis. (A) Hypoxia was evaluated using pimonidazole staining. (B) 
Necrosis was evaluated by H&E staining. (A, B) Representative images are shown for the control group at day 11 before initiating treatment (control day 11) 
and at day 30 for the control group (PBS treated) (control day 30) and, bevacizumab and ABT-510-treated groups. Magnification is indicated on the images. 
Graphs represent the percentage of hypoxic (A) and necrotic (B) area for each experimental group (control, bevacizumab and ABT-510).
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growth at early time-points during tumor progression (Figs. 2 
and 3). This dramatic change in HIF reporter activity was 
followed by a linear increase in reporter activity that paralleled 
an increase in tumor size (Fig. 3). Our interpretation of this 
sharp increase of reporter activity is that it preceded the tumor 
angiogenic switch and, therefore, was a consequence of hypoxia 
caused by initial tumor growth in the absence of angiogenesis. 
The subsequent linear increase in the HIF reporter could be 
explained by a number of interpretations: i) although 9xHRE-
luc reporter was strictly silent in OVCAR-3 cells in vitro, we 
cannot rule out a significant basal activity of the reporter in vivo, 
ii) compensation of hypoxia by neovascularization once the 
angiogenic switch is operating and iii) secondary peaks of HIF 
reporter could be masked by decreased cell viability (necrosis). 
The reported dynamics of functional HIF reporters monitored 
by optical imaging were highly variable depending on the tumor 
model: subcutaneous allograft (26) vs. subcutaneous orthotopic 
xenograft (24) or our data in subcutaneous xenografts. This vari-
ability most probably reflects differences in tumor growth rate 
and patterns of tumor vascularization. In our study, OVCAR-3 
subcutaneous xenografts displayed significant necrotic areas, 
despite being highly vascularized tumors; pointing to exacer-
bated but defective tumor angiogenesis unable to cope with the 
tumor expansion rate. These characteristics could underlie the 
gradual increase in HIF reporter even in large tumors, where 
activation of the reporter by hypoxia could be compensated by 
increased neovascularization, followed by decreased number 
of viable cells due to deficient perfusion. In agreement, Fig. 5A 
shows that pimonidazole staining increases during tumor 
growth, which is compatible with the trend observed for the 
reporter at those time-points (Fig. 2B).
As OVCAR-3 tumors were highly vascularized, we expected a 
good response to antiangiogenic therapy, which was confirmed 
in the case of bevacizumab treatment. Unexpectedly, we 
detected a gradual decrease in HIF reporter activity over the 
duration of bevacizumab treatment. In the few publications that 
evaluated the effect of bevacizumab using a luminescent HIF 
reporter results were divergent: activation of the reporter in a 
lung adenocarcinoma model (15) and inhibition of the reporter 
in a glioblastoma model (16). A decrease in HIF reporter 
activity by antiangiogenic treatment could be explained by: i) a 
decrease in intratumoral hypoxia caused by vascular normal-
ization; ii) an increase in intratumoral hypoxia that may cause 
a decrease in luciferase activity due to limited oxygen avail-
ability; iii) reduced availability of luciferase substrate as a 
consequence of reduced vascularization; and iv) an increase 
in intratumoral hypoxia compensated with a decrease in the 
number of viable cells. In our study we reasoned that: i) vascular 
normalization was an unlikely explanation, as the decrease in 
HIF reporter imposed by bevacizumab treatment lasted 14 
days; and ii) oxygen/luciferin availability was also ruled out, 
as HIF reporter was activated to the same extent by external 
hypoxia imposed on bevacizumab, ABT-510 and control mice 
(Fig. 3C); and iii) the compensation on HIF reporter activity of 
opposing increased intratumoral hypoxia and decreased tumor 
size caused by induction of necrosis by bevacizumab treatment 
which was the favored explanation based on evaluation of 
biological parameters in OVCAR-3 tumors ex vivo. A further 
factor that could contribute to loss of reporter signal in large 
tumors treated with bevacizumab is the inactivation of the HIF 
pathway as consequence of exposure to sustained hypoxia. In 
fact, in vitro experiments have demonstrated the existence 
of a HIF-mediated negative feed-back loop (30). Moreover, 
HIF-mediated metabolic adaptation results in lower oxygen 
consumption by the cells and thus higher availability of oxygen 
that could lead to HIF-degradation. Regardless of the mecha-
nism, the inactivation of HIF activity upon sustained hypoxia 
in vivo has been previously reported (26). Finally, consistent 
with unresponsiveness of OVCAR-3 tumors to an alternative 
antiangiogenic treatment using ABT-510, no differences in 
HIF reporter activity or percentage of necrotic areas were 
detected in the ABT-510 group compared to the control group. 
In contrast to our data, it has been recently demonstrated that, 
in an orthotopic syngeneic mouse model of ovarian cancer, 
ABT-510 treatment reduced tumor microvessel density and 
increased the percentage of mature blood vessels (31) resulting 
in increased efficacy of chemotherapeutic drugs when used 
in combination with ABT-510 (32). Lack of responsiveness to 
ABT-510 in our model of subcutaneous xenotransplant could 
be attributed to significant differences in the pattern of tumor 
vascularization or angiogenic balance.
In summary, our results showed that, in OVCAR-3 subcu-
taneous xenografts, the most abrupt change in HIF functional 
reporter occurs before the onset of massive tumor growth. 
Subsequent peaks of HIF reporter activation may be masked 
by decreased tumor cell viability induced by tumor hypoxia 
caused by tumor growth or forced by antiangiogenic treat-
ment. Although a number of articles have been published 
over the last five years addressing the functional monitoring 
of HIF stabilization or HIF activation by optical imaging 
(19,24,26,27,33,34); very few studies have investigated the 
usefulness of these functional reporters to monitor changes 
in HIF stabilization induced by antiangiogenic treatment. 
Further analysis in a variety of tumor models and using 
diverse antiangiogenic strategies is required to expand our 
view of the usefulness and possible limitations of functional 
HIF reporters to monitor changes in HIF induced by anti-
angiogenic treatment.
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